Melanoma is a type of skin cancer that begins in skin cells called melanocytes. Although it accounts for only about 1% of skin cancers, it causes a large majority of skin cancer deaths. Anti-PD-1 monoclonal antibodies like Merck's Keytruda and Bristol Myers Squibb's Opdivo are mostly used to treat melanoma and have significantly improved survival outcomes in patients with advanced melanoma. However, a subset of patients develop resistance to PD-1 inhibition.
The company we are profiling today is Replimune Group Inc. (REPL), a clinical-stage biotechnology company that has developed a treatment for anti-PD1 failed melanoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com